CLINUVEL Advances Controlled-Release Peptide Platform with VLRX-L
CLINUVEL Pharmaceuticals Limited (ASX: CUV) has begun administering doses in an early-stage study designed to assess its newly developed liquid-based injectable peptide delivery platform, known as VLRX-L, which is engineered to provide controlled and sustained release of therapeutic peptides. Developed in-house at the company’s VALLAURIX Research, Development & Innovation Centre in Singapore, the platform is designed to enable flexible, controlled delivery of peptides, including melanocortin-based therapies. The ongoing study focuses on safety, pharmacokinetics, and reproducibility of drug release using in-vitro models, with preliminary results expected in the second half of 2026.
VLRX-L represents the first novel platform to enter CLINUVEL’s preclinical program following more than a decade of research into peptide design, polymers, and delivery systems. The initiative is supported by an expanded five-year investment plan at the Singapore RD&I Centre, backed by the Singapore Economic Development Board, aimed at strengthening formulation and analytical capabilities. If successful, CLINUVEL intends to explore scale-up and commercialisation pathways, broadening its proprietary pipeline and long-term therapeutic options
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
CLINUVEL Advances Controlled-Release Peptide Platform with VLRX-L
CLINUVEL Pharmaceuticals Limited (ASX: CUV) has begun administering doses in an early-stage study designed to assess its newly developed liquid-based injectable peptide delivery platform, known as VLRX-L, which is engineered to provide controlled and sustained release of therapeutic peptides. Developed in-house at the company’s VALLAURIX Research, Development & Innovation Centre in Singapore, the platform is designed to enable flexible, controlled delivery of peptides, including melanocortin-based therapies. The ongoing study focuses on safety, pharmacokinetics, and reproducibility of drug release using in-vitro models, with preliminary results expected in the second half of 2026.
VLRX-L represents the first novel platform to enter CLINUVEL’s preclinical program following more than a decade of research into peptide design, polymers, and delivery systems. The initiative is supported by an expanded five-year investment plan at the Singapore RD&I Centre, backed by the Singapore Economic Development Board, aimed at strengthening formulation and analytical capabilities. If successful, CLINUVEL intends to explore scale-up and commercialisation pathways, broadening its proprietary pipeline and long-term therapeutic options
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au